Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jill E Slansky

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
Plos Biology|December 24, 2003
Antigen-specific T cells: analyses of the needles in the haystackJill E Slansky
Seminars in Immunology|March 25, 2020
Peptide mimotopes alter T cell function in cancer and autoimmunityJill E Slansky, Maki Nakayama
Oncoimmunology|June 5, 2013
Mimotope vaccine efficacy gets a "boost" from native tumor antigensJonathan D Buhrman, Jill E Slansky
The New England Journal of Medicine|February 28, 2019
Alternative Splicing in Tumors - A Path to Immunogenicity?Jill E Slansky, Paul T Spellman
Immunologic Research|September 1, 2012
Improving T cell responses to modified peptides in tumor vaccinesJonathan D Buhrman, Jill E Slansky
Plos Biology|September 22, 2010
The Goldilocks model for TCR-too much attraction might not be best for vaccine designJill E Slansky, Kimberly R Jordan
Molecular Carcinogenesis|May 10, 2020
T-cell receptor affinity in the age of cancer immunotherapyMichele M Hoffmann, Jill E Slansky
Anticancer Research|April 12, 2012
Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancerAlexis L Franks, Jill E Slansky
Seminars in Cancer Biology|July 27, 2007
Mobilizing the low-avidity T cell repertoire to kill tumorsRachel H McMahan, Jill E Slansky
Pharmaceuticals (Basel, Switzerland)|October 23, 2021
Implications of Antigen Selection on T Cell-Based ImmunotherapyFaye A Camp, Jill E Slansky
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Plos Biology|December 24, 2003
Antigen-specific T cells: analyses of the needles in the haystackJill E Slansky
Seminars in Immunology|March 25, 2020
Peptide mimotopes alter T cell function in cancer and autoimmunityJill E Slansky, Maki Nakayama
Oncoimmunology|June 5, 2013
Mimotope vaccine efficacy gets a "boost" from native tumor antigensJonathan D Buhrman, Jill E Slansky
The New England Journal of Medicine|February 28, 2019
Alternative Splicing in Tumors - A Path to Immunogenicity?Jill E Slansky, Paul T Spellman
Immunologic Research|September 1, 2012
Improving T cell responses to modified peptides in tumor vaccinesJonathan D Buhrman, Jill E Slansky
Plos Biology|September 22, 2010
The Goldilocks model for TCR-too much attraction might not be best for vaccine designJill E Slansky, Kimberly R Jordan
Molecular Carcinogenesis|May 10, 2020
T-cell receptor affinity in the age of cancer immunotherapyMichele M Hoffmann, Jill E Slansky
Anticancer Research|April 12, 2012
Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancerAlexis L Franks, Jill E Slansky
Seminars in Cancer Biology|July 27, 2007
Mobilizing the low-avidity T cell repertoire to kill tumorsRachel H McMahan, Jill E Slansky
Pharmaceuticals (Basel, Switzerland)|October 23, 2021
Implications of Antigen Selection on T Cell-Based ImmunotherapyFaye A Camp, Jill E Slansky
Pageof 6